IVB-001 is under clinical development by VGI Health Technology and currently in Phase II for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IVB-001 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IVB-001 overview

IVB-001 is under development for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It is administered through sublingual route. The drug candidate is a tocotrienol (T3) that is being developed based on TransT3 delivery platform which enhance absorption of T3 by facilitating sublingual and buccal absorption.

VGI Health Technology overview

VGI Health Technology (VTL) is a company that specializes in the development and commercialization of evidence-based nutraceuticals and pharmaceuticals. The company offers a range of products including dietary supplements, health and therapeutic products, and nutraceutical drugs. VTL has various brands such as nE1-Heart, nE1-Elite, and MELT3. The company’s products are used in various industries for health and wellness purposes. It’s services extend to research, development, and distribution of nutraceuticals and pharmaceuticals products. VGI is headquartered in Sydney, New South Wales, Australia.

For a complete picture of IVB-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.